AAN 2021 | REGAIN study and extension trial of eculizumab in myasthenia gravis

James F. Howard, Jr., MD, FAAN, University of North Carolina School of Medicine, Chapel Hill, NC, discusses the findings from the REGAIN study (NCT01997229) and its open-label extension trial (NCT02301624) of eculizumab, a terminal complement inhibitor, in patients with refractory anti-acetylcholine receptor antibody-positive generalized myasthenia gravis. Patients experienced rapid improvements with eculizumab across muscle groups and in associated daily activities. These improvements were sustained through the open-label extension. This interview took place during the American Academy of Neurology (AAN) 2021 Annual Meeting.